Forty Seven, Inc. (FTSV)
(Delayed Data from NSDQ)
$18.35 USD
+0.35 (1.94%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$18.35 USD
+0.35 (1.94%)
Updated May 3, 2019 04:00 PM ET
After-Market: $18.27 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Demand for Essential Goods Rises Amid Coronavirus: 3 Winners
by Zacks Equity Research
Despite the lagging markets, companies that offer pharmaceuticals and FMCG products have witnessed a surge in recent weeks, largely driven by strong demand for their goods.
Top Ranked Momentum Stocks to Buy for March 30th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 30th
Coronavirus Scare Supports These Biotech ETFs & Stocks
by Sanghamitra Saha
Growing coronavirus concerns provide some support to these biotech ETFs and stocks amid a massive market sell-off.
4 Big Drug/Biotech Stocks Up in Coronavirus-Hit Economy
by Kinjel Shah
Here we highlight four bigshot drugmakers/biotechs whose stocks are up this year in spite of the coronavirus impact.
Gilead (GILD) Announces Positive Long-Term Results on Descovy
by Zacks Equity Research
Gilead (GILD) announces long-term results from the DISCOVER study, which showed that Descovy is effective for HIV prevention with non-inferior efficacy to Truvada.
Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More
by Zacks Equity Research
The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.
Company News for Mar 3, 2020
by Zacks Equity Research
Companies in the news are: FTSV, MINI, KPTI ATEC
Gilead to Buy Immuno-Oncology Company Forty Seven for $4.9B
by Zacks Equity Research
Gilead (GILD) looks to strengthen its immuno-oncology research and development portfolio with the acquisition of Forty Seven.
Healthcare Drives Wall Street: 5 Soaring ETFs & Stocks
by Sanghamitra Saha
Decent fundamentals and valuations as well as encouraging developments put these medical ETFs and stocks in focus.
Top Ranked Momentum Stocks to Buy for April 25th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 25th